Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 1

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 1
---
 at March 31, 2025 and December 31, 2024, respectively; liquidation preference of $2,537,000 at March 31, 2025 
     982,143  
     1,249,999 
  
    Series A convertible preferred stock, $0.0001 par value; 12,580 shares authorized; 1,429 and 1,894 issued and outstanding at March 31, 2025 and December 31, 2024, respectively; liquidation preference of $1,429,000 at March 31, 2025 
     1,287,315  
     1,708,396 
  
    Series B convertible preferred stock, $0.0001 par value; 626 shares authorized; 198 and 273 issued and outstanding at March 31, 2025 and December 31, 2024, respectively; liquidation preference of $198,000 at March 31, 2025 
     158,147  
     218,051 
  
    Class A common stock; $0.0001 par value; 1,000,000,000 shares authorized; 5,169,723 and 2,415,883 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively 
     517  
     242 
  
    Additional paid-in capital 
     73,345,026  
     67,142,046 
  
    Stock subscription receivable 
     (78,750) 
     (1,295,444)
  
    Accumulated deficit 
     (76,023,784) 
     (70,917,853)
  
    Total stockholders’ deficit 
     (329,386) 
     (1,894,563)
  
    Total liabilities and stockholders’ deficit 
    $7,991,414  
    $6,206,929 

See accompanying notes to the condensed consolidated financial statements

1

CERO THERAPEUTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

    For the  Three  Months  Ended  March 31,  2025  
    For the  Period from  February 14,  2024  through  March 31,  2024